Articles tagged with Breast Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A large clinical trial found that black women with hormone-receptor positive breast cancer had a higher risk of recurrence and death compared to white women, even when treated equally. The study suggests biological differences may contribute to the disparity in outcomes.
A phase III trial found T-DM1 significantly reduced invasive disease-free survival risk in patients with HER2-positive early-stage breast cancer and residual invasive disease after neoadjuvant chemotherapy and trastuzumab. The treatment also showed promise in reducing recurrence risk across various subgroups of patients.
Pathological complete response after neoadjuvant chemotherapy was associated with lower recurrence risk and higher overall survival in breast cancer patients. The association between pCR and outcomes was similar among those who received additional adjuvant chemotherapy versus those who did not.
A recent study presented at EuroEcho-Imaging 2018 suggests that breast cancer patients who take the beta-blocker carvedilol together with trastuzumab have better-preserved left ventricular function compared to those who take trastuzumab alone. This may indicate that carvedilol can help prevent heart damage caused by trastuzumab treatment.
A retrospective study found that patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy had a significantly higher risk of disease recurrence and death. The study suggests that initiating chemotherapy within 30 days after surgery is crucial for improving disease-free and overall survival rates.
A recent study found that adding adjuvant capecitabine to standard treatment did not significantly improve disease-free or overall survival for patients with early-stage triple-negative breast cancer. However, a subset of patients with nonbasal-like disease showed a significant benefit from capecitabine.
Researchers at UC San Diego School of Medicine developed a method to turn B cells into factories that assemble and secrete vesicles containing tumor-suppressing microRNAs. In mice, breast tumors treated with this approach were significantly smaller than untreated tumors, and the treatment was long-lasting.
Researchers at SWOG share findings from three studies on breast cancer subtypes, treatment response, and recurrence. The studies used existing trial data to identify subsets of patients and tumors with distinct characteristics, which can inform treatment decisions.
Researchers at Lund University identified three types of connective tissue cells that affect breast cancer development and metastasis. Patients with vascular fibroblasts or matrix fibroblasts in their tumours have a worse prognosis.
A recent study found that around 72% of women at higher risk of breast cancer are worried about the long-term effects of tamoxifen, while 57% believe it will give them unpleasant side-effects. Despite its proven ability to prevent breast cancer, fewer than 15% of women with discussed preventive therapy are taking tamoxifen.
Scientists have developed a new system to rapidly and accurately detect tumor margins during breast cancer surgery, using a 'click-to-sense' acrolein probe that conjugates with live breast cancer cells. The method has been shown to be highly sensitive and selective, with a 97% accuracy rate.
A new smartphone app designed for breast cancer survivors has been shown to help patients achieve significant weight loss and improvements in physical activity. The app, created at Houston Methodist, allows users to interact with their healthcare team and receive real-time feedback and guidance from a clinical dietitian.
Researchers have reported promising preliminary results for cryoablation as a treatment for low-risk breast cancers, with a 99.4% success rate and no serious adverse events. The procedure is being studied as an alternative to surgical lumpectomy.
Researchers at the University of California San Diego have developed a simple 3D bioprinting technique using natural materials to create lifelike organ tissue models. The method allows for the creation of vascularized human gut and blood vessel networks capable of keeping cancer tumor tissues alive outside the body.
A large-scale study found that annual mammography screening starting at age 30 may benefit women with specific risk factors. Women with dense breasts, a personal history of breast cancer, or a family history of breast cancer had increased breast cancer risk and benefited from earlier screening.
Researchers have discovered that dasatinib sensitizes triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Additionally, a systematic review and meta-analysis found an increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy.
A new study found that breast cancer treatment correlates with accelerated biological aging and declines in cognitive function. Women who underwent breast cancer treatment several years earlier showed lower executive function scores, attention, and motor speed due to higher DNA damage and lower telomerase activity.
Researchers found that breast tumors can recruit bone marrow-derived fibroblasts to boost growth and metastasis. These cells lack key signaling proteins and produce clusterin, promoting blood vessel formation and tumor progression.
A new study confirms that women aged 75 and older should continue receiving mammography screenings due to the significant risk of breast cancer in this age group. The research found a considerable incidence of breast cancer among women over 75, with most cases being invasive and treatable.
A new report from the American Cancer Society proposes key areas to advance cancer screening's contribution to cancer control. Research is needed to improve existing screening modalities, quality and performance of current tests, and develop new strategies for cancers amendable to screening.
Research reveals that women who undergo reconstructive surgeries using a large back muscle after radiation therapy experience significant losses in shoulder stability and function. Conversely, other methods such as pectoral muscle rebuild and abdominal tissue transfer produce equally good results for future shoulder function.
Scientists at UNC Lineberger Comprehensive Cancer Center develop a computer algorithm to analyze breast cancer images and identify tumor characteristics. The AI system achieves high accuracy in distinguishing between low-intermediate and high-grade tumors, as well as estrogen receptor status and molecular subtypes.
Researchers found that flunarizine can slow down the growth of triple-negative breast cancer in an animal model, and it promotes N-Ras degradation. This approach is quicker and less expensive than traditional drug development strategies.
Researchers are testing Precision Breast IORT, which uses advanced imaging to tailor radiation treatment and potentially improve outcomes for patients with early-stage breast cancer. The study aims to evaluate the technique's effectiveness in reducing breast cancer recurrence rates and immune-dampening effects.
Purdue University researchers have developed a technology that uses nanoparticles to target cancerous cells and tumors, providing more effective and safer chemotherapy treatment. The method has been tested on breast cancer and melanoma models and shows promise for treating various types of cancerous tumors.
Researchers found two genomic tests, MammaPrint and BluePrint, can predict patient response to new treatments. These tests identified subgroups of patients with high-risk tumours more likely to respond to specific therapies.
Scientists at EPFL have found that half of luminal epithelial breast cells express estrogen receptor at low levels, affecting cell function and cancer development. The estrogen receptor plays a biphasic role in breast cell growth and inhibition during pregnancy.
Women who participate in breast screening have a significantly lower risk of dying from breast cancer within 10 and 20 years after diagnosis. The study found that screening detects cancers at an earlier stage, allowing for more effective treatment and a reduced mortality rate.
Researchers have developed a new strategy against HER2-driven lung cancers using tarloxotinib, a potent HER2/EGFR inhibitor that is more active in low-oxygen conditions than existing therapies. This innovative approach has shown significant promise in treating patients with HER2 lung cancer.
Researchers will identify biomarkers for DNA repair defects in tumors, enabling faster decision-making on treatment choices. A clinical trial will test carboplatin therapy's effectiveness in advanced prostate cancer.
A recent study published in the British Journal of Cancer found a positive association between type 2 diabetes and an increased risk of colorectal cancer (CRC) in men, with a moderately higher risk observed. In contrast, the association was weaker and not statistically significant for women. The study followed up over 87,000 women and ...
A synthetic compound based on a brain hormone has shown surprising benefits in treating lung and other cancers in mice, but its effect on human cells was the opposite. The compound, MR409, is one of several GHRH analogs that spur healthy tissue growth and may alleviate concerns about stimulating cancer cell growth.
A study of genetic variants found that morning preference reduces the risk of breast cancer by 40-48% compared to evening types. Increased sleep duration and insomnia were associated with a 20% increased risk of breast cancer.
A study published in Psycho-Oncology found that women who have survived breast cancer are more likely to experience phobic anxiety, leading to sexual dysfunction and unpleasant sex experiences. The research highlights the significant role of psychosocial factors on sexuality in these patients.
A prognostic model using machine learning accurately stratifies African-American breast cancer patients into high- and low-risk populations based on protein expression levels. The model identifies a combination of four proteins associated with increased risk of death, suggesting specific therapeutic regimens for this underserved demogr...
A new study reveals that states expanding Medicaid from 2011 to 2017 experienced a significant 27% increase in prescriptions for hormonal therapy medications compared to non-expansion states. This rise was attributed to increased access for previously uninsured women who required long-term treatment with these life-saving drugs.
Women carrying rare breast cancer variants are more likely to develop interval breast cancers, which are often aggressive and lethal. The study found that these women have a higher risk of death from breast cancer compared to those with common mutations.
Researchers at the University of Cincinnati have developed a molecular diagnostic test that can assess breast cancer risk based on Osteopontin variants. The test helps patients and doctors make informed decisions about treatment options, weighing aggressive intervention against waiting for potential progression.
A new study finds that women receiving hormone-blocking injections during chemotherapy have a higher chance of becoming pregnant without negative side effects. The injections protect the ovaries from chemotherapy's effects, reducing the risk of early menopause and improving survival rates.
Long-term data show that whole breast radiation therapy significantly reduces the risk of local recurrence in low-risk ductal carcinoma in situ (DCIS) patients, even without additional treatment. Radiation also reduces overall cancer return by more than 70 percent.
Researchers investigated alternative radiation therapy regimens for early-stage breast cancer patients. The trial found that fewer, larger individual doses of radiation led to similar adverse effects as conventional radiation therapy after 10 years.
Researchers found that common genetic variations can significantly increase breast cancer risk for female pediatric cancer survivors, with a two-fold higher risk compared to average survivors. The collective effect of these variations is comparable to having a high-risk mutation in breast cancer predisposition genes.
A study of female childhood cancer survivors found that genetic profiling can identify high-risk individuals for subsequent breast cancer. Polygenic determinants and rare mutations significantly contribute to breast cancer risk, with a notable age-specific association in younger women.
A survey of 724 women found that nearly 60% knew about the link between breastfeeding and breast cancer risk reduction, but only 16% learned it from a medical professional. The study highlights the importance of healthcare providers educating mothers about the benefits of breastfeeding in reducing breast cancer risk.
A phase III clinical trial found that palbociclib improves overall survival in women with hormone receptor-positive metastatic breast cancer. The drug, used in combination with standard treatment, led to a clinically meaningful improvement in median overall survival, even in patients who showed sensitivity to prior hormone therapy.
Researchers found that half of the Spanish-speaking women did not receive letters in their native language, leading to confusion and misinterpretation of key messages. The study highlights the importance of culturally sensitive communication and timely follow-up for women with dense breasts.
Researchers developed a nanofluidic seed that can deliver sustained-release doses of immunotherapy directly to tumors, reducing the need for multiple IV treatments and eliminating side effects. The device has shown promising results in mice models, with equal effectiveness compared to systemic immunotherapy while minimizing toxicities.
The HOBOE-2 trial found that zoledronic acid plus letrozole improved disease-free survival in premenopausal women with HR+ early breast cancer, with a 5-year DFS probability of 0.93 compared to 0.85 for tamoxifen. The combination treatment reduced breast cancer recurrence and mortality by nearly half.
A study published in Nature Genetics found that long non-coding RNA MALAT1 suppresses breast cancer metastasis, contradicting its previously described role as a metastasis promoter. The researchers used mouse models to show that MALAT1 binds and inactivates TEAD, a transcription factor involved in promoting metastasis.
A phase III trial demonstrated that chidamide, an HDAC inhibitor, improves progression-free survival compared to placebo plus exemestane in patients with hormone receptor-positive advanced breast cancer. Serious adverse events were reported, but the treatment regimen was generally well-tolerated.
A new study shows that targeting the specific genomic mutation PIK3CA in hormone receptor-positive HER2-negative advanced breast cancer patients significantly improves progression-free survival. The study found that nearly twice as long PFS was observed in patients with PIK3CA mutations treated with alpelisib compared to the placebo gr...
The PALOMA-3 study found that the CDK4/6 inhibitor palbociclib significantly improves progression-free survival in patients with HR+/HER2- advanced breast cancer. In a new analysis, palbociclib plus fulvestrant was shown to improve overall survival by 6.9 months compared to placebo plus fulvestrant.
Atezolizumab, an antibody targeting PD-L1, improved survival in metastatic triple negative breast cancer patients by 20%, particularly those with PD-L1 positive tumors. The combination therapy also reduced disease worsening and death risk by 38% in PD-L1 positive subgroup
A large study found that drugs approved for women's breast cancer are also effective and well-tolerated in men. Men with metastatic breast cancer received similar treatments to women, including hormonal therapy and chemotherapy, with similar outcomes.
A Phase III clinical trial shows that combining immunotherapy with chemotherapy improves progression-free and overall survival for patients with triple-negative breast cancer. The study's results establish a new standard of care in PD-L1+ patients and provide hope for those diagnosed with this aggressive form of breast cancer.
A combination of immunotherapy and chemotherapy significantly extends survival by up to ten months in patients with triple-negative breast cancer. The treatment reduces the risk of death or cancer progression by up to 40 per cent, offering new hope for young women affected by this aggressive form of breast cancer.
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer. The combination treatment lived seven months longer than hormone treatment alone, with benefits strongest in women who had previously responded to hormone therapy.
A recent survey found that social vulnerability and medical skepticism are major barriers to cancer screening participation, particularly for colorectal and lung cancer screenings. Researchers call for a combined approach incorporating new technologies and personalized messaging to address inequalities in screening uptake.
French researchers conclude that including exercise in cancer care can significantly improve symptom management, quality of life, and fitness. Studies show that regular exercise reduces pain, fatigue, and body fat while improving overall fitness, with benefits seen even among patients at highest risk of poor quality of life.
A nine-week course of adjuvant trastuzumab was associated with similar disease-free survival and lower risk of cardiac toxicity compared to a one-year course in patients with HER2-positive early breast cancer. A six-month course of trastuzumab was also shown to be cost-effective, with an average cost saving of nearly £10,000 per patient.